The Cancer Immunotherapy Market is undergoing a significant transformation, driven by rapid advancements in biotechnology, increasing cancer prevalence, and growing adoption of immune-based therapies. The Cancer Immunotherapy Market size is projected to reach US$ 319,946 million by 2031, expanding at a CAGR of 12.4% during 2025–2031. This strong growth reflects the increasing demand for...

In-Depth Study on Executive Summary Cancer Immunotherapy Market Size and Share CAGR Value The global cancer immunotherapy market size was valued at USD 95.69 billion in 2024 and is expected to reach USD 28.27 billion by 2032, at a CAGR of 15.50% during the forecast period This growth is driven by factors such as the increasing prevalence of cancer...

Immune checkpoint inhibitors are advanced immuno oncology drugs that block inhibitory pathways used by cancer cells to evade immune system detection. These therapies target immune checkpoints such as CTLA 4, PD 1, and PD L1 to activate immune responses against tumors. Their effectiveness in improving survival rates across different cancer indications has significantly transformed modern...

Neoantigens are tumor specific antigens generated from genetic mutations that occur only in cancer cells, making them highly precise therapeutic targets. Their ability to trigger strong immune responses without harming normal tissues makes them central to next generation cancer immunotherapy strategies. Ongoing advancements in genomic sequencing are expanding the identification of clinically...